Dornase alfa

Dornase alfa
Clinical data
Trade names	Pulmozyme
AHFS/Drugs.com	Monograph
MedlinePlus	a694002
License data	US DailyMed: Dornase alfa;
Pregnancy; category	AU: B1; ;
Routes of; administration	Inhalation
ATC code	R05CB13 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; US: ℞-only; In general: ℞ (Prescription only);
Identifiers
CAS Number	143831-71-4 ;
DrugBank	DB00003 ;
ChemSpider	none;
UNII	953A26OA1Y;
KEGG	D03896;
CompTox Dashboard (EPA)	DTXSID801010888 ;
ECHA InfoCard	100.029.685
Chemical and physical data
Formula	C1321H1999N339O396S9
Molar mass	29254.04 g·mol−1
	(what is this?) (verify)

Dornase alfa, sold under the brand name Pulmozyme, is used for the treatment of cystic fibrosis.^[3] It is a recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA.^[3] Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions.^[3] It is produced in Chinese hamster ovary cells.^[3]

Medical uses

Dornase alfa is indicated for the management of people with cystic fibrosis to improve pulmonary function.^[3]

Society and culture

Legal status

Dornase alfa is an orphan drug.^[4]

Research

Dornase alfa has been shown to improve lung function in non-cystic fibrosis pre-term infants atelectasis.^[5]^[6]

References

[3]

[1]

[2]

[4]

[5]

[6]

Search